Search Results
Mar 31, 2026, 10:00 ET American Eagle Financial Credit Union Hosts 3rd Annual Financial Reality Fair for High School Students Across Greater Hartford
housing, transportation, food, entertainment, and furniture—to build a monthly budget. Along the way, they made choices, encountered surprises, and met with "financial counselors" to learn how to balance wants vs. needs. "At American Eagle, our mission is not only to educate local residents –
More news about: American Eagle Financial Credit Union
Mar 31, 2026, 10:00 ET Cambiar Thrive's "Big Ideas Challenge" Awards $2M+ to Put the Power of Data in the Hands of Students and Families to Fuel Student-Led Success
data more accessible and actionable than ever before. This work also unlocked key insights into the systemic need for solutions–and how they can be met. To accelerate our mission of closing the education information gap, Cambiar Thrive plans to publish these insights to catalyze broader innovation and
More news about: Cambiar Education
Mar 31, 2026, 09:44 ET De zvoove-groep verwerft KleanApp
multimodale tijdtracking. De oplossing wordt gebruikt in duizenden objecten en faciliteiten in de DACH-regio.Met deze overname exploiteert zvoove Clean nu een uitgebreid Europees platform met meerdere producten. De combinatie creëert een unieke softwarestack die in staat is om de volledige operationele
More news about: Zvoove Group GmbH
Mar 31, 2026, 09:36 ET Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injection, have successfully met their pre-specified primary endpoints. After 26 weeks of treatment, once-weekly GZR4 demonstrated statistically significant superior efficacy in reducing
More news about: Gan & Lee Pharmaceuticals
Mar 31, 2026, 09:05 ET L'audit du SEC 2026 révèle une croissance de quatre pour cent de la participation, alors que les innovateurs étaient présents à Las Vegas
augmentation de la fréquentation à 148 392 participants. L'audit confirme que le CES est le centre d'affaires de toute la communauté technologique mondiale et met à l'honneur les personnes et les idées derrière les technologies qui améliorent la qualité de vie.
More news about: Consumer Technology Association
Mar 31, 2026, 09:00 ET LC Sign Empowers Visually Impaired Students with Landmark Braille Project and Launches 'The Touchpoint Initiative'
school grounds. In response, LC Sign worked closely with special education professionals and accessibility consultants, ensuring that every new sign met high standards for tactile accuracy and durability. The innovative signage features optimized braille design for easier reading by touch, high-contrast
More news about: Guangzhou LC Sign Co., Ltd.
Mar 31, 2026, 09:00 ET LC Sign Empowers Visually Impaired Students with Landmark Braille Project and Launches 'The Touchpoint Initiative'
school grounds. In response, LC Sign worked closely with special education professionals and accessibility consultants, ensuring that every new sign met high standards for tactile accuracy and durability. The innovative signage features optimized braille design for easier reading by touch, high-contrast
More news about: Guangzhou LC Sign Co., Ltd.
Mar 31, 2026, 09:00 ET MREO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Mereo BioPharma Group plc Securities Lawsuit -- The Gross Law Firm
release announcing that neither the ORBIT nor the COSMIC Phase 3 studies achieved statistical significance. The press release indicated that neither study met its primary endpoint of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively, despite improved bone mineral
More news about: The Gross Law Firm
Mar 31, 2026, 08:58 ET Co-PSMA data published in the European Urology journal
biochemical recurrence, potentially enabling more precise and timely salvage treatment strategies."As previously reported, the Co-PSMA trial met its primary endpoint, demonstrating that 64Cu-SAR-bisPSMA (next-day imaging) identified more than twice as many cancer lesions per patient
More news about: Clarity Pharmaceuticals
Mar 31, 2026, 08:38 ET MCE 2026: Midea presenteert zijn professionele service-ecosysteem voor 'Green Vision, Blue Future'
op de energietransitiedoelstellingen van Europa presenteerde Midea warmtepompboilers met energielabel A++, gasboilers met lage NOx-uitstoot en zonnegeïntegreerde modellen die naadloos kunnen worden gesynchroniseerd met residentiële PV-systemen. De oplossingen geven prioriteit aan duurzaamheid (bijvoorbeeld
More news about: Midea Building Technologies
Mar 31, 2026, 08:15 ET Ramaco Resources, Inc. Announces Internal Corporate Reorganization
include, without limitation, unexpected delays in our current mine development activities, the ability to successfully increase production at our existing met coal complexes in accordance with the Company's growth initiatives, failure of our sales commitment counterparties to perform, increased government regulation
More news about: Ramaco Resources, Inc.
Mar 31, 2026, 07:37 ET Icon Global Named Official Partner of FEI World Cup™ Finals 2026 in Fort Worth
for competitors, sponsors, and spectators alike. SRJT's first event in Fort Worth, the Fort Worth International CSI4*-W, was held in December 2021 and met with rave reviews and sell-out crowds. More information on the SRJT can be found at
More news about: Icon Global Group, LLC
Mar 31, 2026, 07:37 ET Icon Global Named Official Partner of FEI World Cup™ Finals 2026 in Fort Worth
for competitors, sponsors, and spectators alike. SRJT's first event in Fort Worth, the Fort Worth International CSI4*-W, was held in December 2021 and met with rave reviews and sell-out crowds. More information on the SRJT can be found at
More news about: Icon Global Group, LLC
Mar 31, 2026, 06:30 ET Keenova Announces Unaudited Fourth Quarter 2025 Financial Results
Toe: Proof-of-concept study enrollment was completed ahead of schedule in November 2025. Topline data demonstrated a favorable safety profile and met secondary and exploratory efficacy endpoints, enabling progression of the program into a registrational Phase 3 study. An FDA end-of-Phase 2 meeting
More news about: Keenova Therapeutics
Mar 31, 2026, 06:00 ET Cambridge Launches Indy, Proprietary AI-Powered Chat Assistant for Advisors
relevanceCompliance and Governance: Every AI interaction is governed with the same rigor as human associates, ensuring security and regulatory standards are metAgentic AI Roadmap: Indy is one step toward a broader AI ecosystem, including autonomous agents capable of handling complex tasks like
More news about: Cambridge
Mar 31, 2026, 04:00 ET RDW: Nederland introduceert op 1 juli 2026 truck toll
ZOETERMEER, Nederland, 31 maart 2026 /PRNewswire/ -- Over vier maanden start Nederland op 1 juli 2026 met truck toll. Net als in meerdere Europese landen betalen eigenaren van vrachtwagens, inclusief buitenlandse trucks, vanaf dan per gereden kilometer. Dit
More news about: RDW
Mar 31, 2026, 04:00 ET Classement des taux réels d'imposition pour un entrepreneur en Europe - Étude Valmerand 2026
aux taux réels d'imposition globaux applicables à un entrepreneur en Europe. Réalisée sur un panel de 30 juridictions européennes, l'étude met en évidence un constat simple : la fiscalité réellement supportée par un dirigeant-actionnaire ne peut pas être lue à travers un seul taux affiché. Elle
More news about: VALMERAND
Mar 31, 2026, 03:16 ET Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program
was conducted at 10 US clinics over 3 months with a total of 25 patients of which 21 were evaluated for efficacy parameters. The trial successfully met its primary endpoint of safety and tolerability, with no drug-related serious adverse events. Encouraging efficacy signals were observed in the trial,
More news about: Cereno Scientific
Mar 31, 2026, 03:12 ET Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program
was conducted at 10 US clinics over 3 months with a total of 25 patients of which 21 were evaluated for efficacy parameters. The trial successfully met its primary endpoint of safety and tolerability, with no drug-related serious adverse events. Encouraging efficacy signals were observed in the trial,
More news about: Cereno Scientific
Mar 31, 2026, 01:00 ET BANDSINTOWN AMÉLIORE LES ANNONCES DE CONCERTS SUR APPLE MUSIC À L'OCCASION DE LA SORTIE D'IOS 26.4
pour bientôt. À propos de Bandsintown :Bandsintown, la première plateforme mondiale de découverte d'événements en direct, met en relation plus de 100 millions de fans inscrits avec des concerts de plus de 700 000 artistes et 65 000 lieux, publiant 2,3 millions d'événements par
More news about: Bandsintown
Mar 30, 2026, 16:05 ET HireQuest Reports Financial Results for Fourth Quarter and Full Year 2025
completion of a proposed transaction, including the receipt of any required shareholder approvals and any required regulatory approvals, will not be met; the possibility that we may be unable to achieve expected synergies and operating efficiencies within an expected time frame or at all and to successfully
More news about: HireQuest
Mar 30, 2026, 10:30 ET $2.5M Pietri family gift to benefit College of Engineering & Computer Science
community that welcomed me, believed in me and provided the academic rigor and personal support that allowed me to flourish," Pietri said. "The mentors I met here, the opportunities I was given and the confidence I gained became the foundation of my career, just as UTulsa had done for my father before me.
More news about: The University of Tulsa
Mar 30, 2026, 08:00 ET Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026
safety and efficacy endpoint (30-day MACCE) was met, with Emboliner demonstrating statistical non-inferiority to control (4.5% vs. 5.0%; p for non-inferiority = 0.0004)Secondary safety/efficacy endpoint: (30-day stroke, VARC 2) was met, with Emboliner demonstrating statistical non-inferiority
More news about: Emboline, Inc.
Mar 30, 2026, 08:00 ET Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026
safety and efficacy endpoint (30-day MACCE) was met, with Emboliner demonstrating statistical non-inferiority to control (4.5% vs. 5.0%; p for non-inferiority = 0.0004)Secondary safety/efficacy endpoint: (30-day stroke, VARC 2) was met, with Emboliner demonstrating statistical non-inferiority
More news about: Emboline, Inc.
Mar 30, 2026, 07:31 ET L'IFPA lance le premier forum africain sur le psoriasis, appelant à une action urgente contre une maladie négligée
attaquer n'est pas facultatif - cela fait partie de la mise en place de systèmes de santé résilients et équitables. Chaque année, le forum de l'IFPA met l'accent sur une région à la fois, en rassemblant les acteurs locaux afin d'encourager les efforts de sensibilisation et d'appeler à une action unie
More news about: IFPA